ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
Renal Insufficiency
IGA Glomerulonephritis
Renal Cell Carcinoma
Carcinoma

Kidney Disease trials near Barcelona, CT, ESP:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Barcelona, Spain and 17 other locations

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. W...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Placebo (Semaglutide)
Drug: Semaglutide

Phase 3

Novo Nordisk
Novo Nordisk

Barcelona, Spain and 32 other locations

Locations recently updated

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

L'Hospitalet de Llobregat, Spain and 338 other locations

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling
Chronic Kidney Disease
Drug: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 112 other locations

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Barcelona, Spain and 312 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Barcelona, Spain and 241 other locations

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Phase 3

Bayer
Bayer

Barcelona, Spain and 80 other locations

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

Phase 2

Novo Nordisk
Novo Nordisk

Hospitalet de Llobregat, Spain and 106 other locations

Locations recently updated

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Barcelona, Spain and 178 other locations

receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Phase 2

Bayer
Bayer

Barcelona, Spain and 210 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems